Has Michael Harris, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,164 in general payments to Michael Harris, MD across 123 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Harris, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Harris, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Harris, MD

Gastroenterology · Tampa, FLNPI 1740427079

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Boston Scientific at 30.5% of the total.

$4,164in general payments, 2019–2025

Across 123 payments — averaging $33.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$1K
AbbVie$1K
Covidien LP$371
Mallinckrodt Hospital Products Inc.$356
Medtronic$207
Johnson & Johnson$176
plus $658 from 17 others

$69,084in research payments, 2019–2025

Across 6 payments — averaging $11,514 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Cook Research Incorporated$69K

What the payments were for

Food & beverage$4,164100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	16	$1,270
AbbVie	63	$1,125
Covidien LP	4	$371
Mallinckrodt Hospital Products Inc.	3	$356
Medtronic	2	$207
Johnson & Johnson	4	$176
Aimmune Therapeutics, Inc.	5	$119
Vivus LLC	4	$58
Amgen	2	$51
Intuitive Surgical	1	$50
Sanofi	2	$45
Baxter Healthcare	2	$42
Merck	2	$38
Lumendi LLC	2	$37
Takeda Pharmaceuticals U.S.A., Inc.	2	$33
Micro-tech Endoscopy USA, Inc.	1	$32
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$29
Lilly USA, LLC	1	$29
Conmed Corporation	1	$24
QOL Medical, LLC	1	$23
Dynavax Technologies Corporation	1	$18
CSL Behring	1	$17
Alnylam Pharmaceuticals Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TERLIVAZ$322
Beacon$263
Creon$246
AXIOS$235
OverStitch Endoscopic Suturing System$164
EndoFlip$146
GENERAL - BILIARY DEVICES$123
Skyrizi$119
EXALT Model D$118
STELARA$118

How this compares

$4,164 in reported general payments places this provider in the 55th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida →

Medicare billing

Part B allowed, 2024

$95,136

Medicare patients

219

Services billed

659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Omeprazole	34	$422

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Tampa

Adnan MuhammadTampa$150K
John JacobsTampa$141K
Renee Marchioni BeeryTampa$126K
Michael DanielTampa$52K
Samuel GidayOrlando$2M
Lukasz KwapiszMiami$1.2M
Jennifer Seminerio-DiehlOrlando$1.1M
Udayakumar NavaneethanSaint Petersburg$1.1M
Ronen AraiCoral Springs$1.1M
Charles SninskyGainesville$983K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →